Details of how to report adverse events are available at the bottom of the page.
For full information on a Roche medicine, please see the relevant Summary of Product Characteristics.
With a focus on diffuse large B-cell lymphoma (DLBCL), Roche is committed to giving patients a chance for a life beyond treatment. Roche shattered a 20-year hiatus by bringing a first line (1L) treatment for DLBCL in the form of POLIVY. This novel approach changed the status quo and raised hope and expectations for people newly diagnosed with DLBCL and their healthcare teams.
Our commitment to patients did not end there. The introduction of COLUMVI provided an option for patients who had relapsed after two or more lines of systemic therapy. Today, we are delighted to be able to fill the gap between 1L and third line and beyond (3L+) therapy, with COLUMVI + gemcitabine and oxaliplatin (GemOx) in second line (2L) for the large number of patients who are ineligible for autologous stem cell transplant (ASCT).
Please see the links above for prescribing information for POLIVY and COLUMVI.
While innovation begins in the lab, we know that real change happens in haematology clinics across the country. With the rapidly changing treatment paradigm, medical education is more important than ever.
As the leading company driving transformation in this area, Roche takes its responsibility seriously to support HCPs in understanding how and when to use the therapeutic approaches that we have brought to the UK. This website is part of our contribution to sharing the latest data and expert perspectives to enhance scientific understanding and clinical practice. Read on and visit the website again as the information and resources will be expanded and updated
over time.
Our commitment to haematology means we offer therapeutic options along the patient pathway of DLBCL. In an area of unmet needs and a heterogeneous disease course, we understand that HCPs value choice and the ability to personalise treatment. Discover where the BSH guidelines recommend Roche products, from 1L to 3L+ treatment of DLBCL.
The treatment of large B-cell lymphoma – Adapted from the British Society of Haematology Guidelines
For the full British Society for Haematology guidance on managing large B cell lymphoma, please click here: Newly diagnosed | Relapsed or refractory
POLIVY in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) is indicated for the treatment of adult patients with previously untreated DLBCL.
POLIVY in combination with bendamustine and rituximab (POLIVY-BR) is indicated for the treatment of adult patients with R/R DLBCL who are not candidates for haematopoietic stem cell transplant.
COLUMVI + GemOx is indicated for the treatment of adult patients with R/R DLBCL not otherwise specified who are ineligible for ASCT.
COLUMVI as monotherapy is indicated for the treatment of adult patients with R/R DLBCL, after two or more lines of systemic therapy.
We are dedicated to supporting HCPs to achieve optimal patient outcomes, If you have any questions about our products, from practical matters to understanding the data, please do not hesitate to contact us.
Contact us to explore more about our portfolio
Abbreviations:
1L, first line; 2L, second line; 3L+, third line and beyond; ASCT, autologous stem cell transplant; BR, bendamustine + rituximab; BSH, British Society for Haematology; CAR-T, chimeric antigen receptor T-cell therapy; CIT, chemoimmunotherapy; DLBCL, diffuse large B-cell lymphoma; GemOx, gemcitabine and oxaliplatin; HCP, healthcare professional; HDT-auto, high-dose therapy with autologous stem cell transplant; IPI, international prognostic index; NICE, National Institute for Health and Care Excellence; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; R-CHP, rituximab, cyclophosphamide, doxorubicin, prednisone; R-GemOx, rituximab, gemcitabine and oxaliplatin; R/R, relapsed/refractory.
References:
- Fox CP, et al. Br J Haematol. 2024;204(4):1178–1192.
- Chaganti S, et al. Br J Haematol;2025;206:1593–1603.
- NHS. National Cancer Drugs Fund list. Available at: https://www.england.nhs.uk/publication/national-cancer-drugs-fund-list/ Accessed: March 2026.
- NICE. Recommendations: guidance [TA883]. NICE; 2023. Available at: https://www.nice.org.uk/guidance/ta883/chapter/1-Recomendations/ Accessed: March 2026.